Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: A randomized controlled trial from Burkina Faso
American Journal of Tropical Medicine and Hygiene, Volume 73, No. 5, Year 2005
Notification
URL copied to clipboard!
Description
Increasing resistance to chloroquine necessitates the evaluation of other antimalarial therapies in Africa. We compared the efficacies of amodiaquine (AQ), sulfadoxine-pyrimethamine (SP), and AQ + SP for the treatment of uncomplicated falciparum malaria in a randomized trial of patients 6 months of age or older in Bobo-Dioulasso, Burkina Faso. Of the 944 patients enrolled, 829 (88%; 53% under 5 years of age) were assigned 28-day efficacy outcomes. For all regimens, early treatment failures were uncommon (< 2%). Considering all treatment failures based on WHO criteria, AQ + SP was most efficacious (failures in 4.2%), followed by SP (9.1%) and AQ (17.9%; P < 0.02 for all pairwise comparisons). Considering only clinical failures, relative efficacies were similar (failures in 2.1% with AQ + SP, 6.5% with SP, and 13.2% with AQ; P < 0.02 for all pairwise comparisons). The risk of recrudescence was lower with AQ + SP (2.1%) compared with SP (6.1%, P = 0.02) and AQ (8.1%, P = 0.001). Risks of new infection were lower with AQ + SP (2.1%) and SP (2.4%) compared with AQ (9.1%, P < 0.001 for both comparisons). No serious adverse events were seen. AQ + SP appears to offer a highly effective, inexpensive, and available therapy for the treatment of uncomplicated malaria in Burkina Faso. Copyright © 2005 by The American Society of Tropical Medicine and Hygiene.
Authors & Co-Authors
Zongo, Issaka D.
Burkina Faso, Ouagadougou
Institut de Recherche en Sciences de la Santé
Dorsey, Grant M.
United States, San Francisco
University of California, San Francisco
Rouamba, Noël
Burkina Faso, Ouagadougou
Institut de Recherche en Sciences de la Santé
Dokomajilar, Christian
United States, San Francisco
University of California, San Francisco
Lankoande, Moise
Burkina Faso, Ouagadougou
Institut de Recherche en Sciences de la Santé
Ouedraogo, Jean Bosco
Burkina Faso, Ouagadougou
Institut de Recherche en Sciences de la Santé
Rosenthal, Philip Jon
United States, San Francisco
University of California, San Francisco
Statistics
Citations: 58
Authors: 7
Affiliations: 2
Identifiers
Doi:
10.4269/ajtmh.2005.73.826
ISSN:
00029637
Research Areas
Health System And Policy
Infectious Diseases
Maternal And Child Health
Study Approach
Quantitative
Study Locations
Burkina Faso